The World Health Organization (WHO) has published its first comprehensive clinical guidelines for managing filovirus diseases—including Ebola and Marburg—amid the Democratic Republic of the Congo’s ongoing Bundibugyo virus outbreak, which has killed at least 123 people since January 2026. The 16 evidence-based recommendations, developed after global expert consultations, prioritize early supportive care to improve survival rates, which range from 25% to 90% in severe outbreaks. Unlike Ebola, no licensed vaccines or treatments exist for Bundibugyo, Sudan, or Marburg viruses, making optimized supportive care the cornerstone of patient survival.
These guidelines arrive as the WHO’s latest effort to standardize care during filovirus outbreaks, which have caused 72 recorded episodes in Africa since 1967. The new protocols aim to harmonize clinical approaches across health systems, ensuring equitable access to life-saving interventions like intravenous fluids, vasoactive drugs, and structured aftercare for survivors. “Early recognition, rapid referral, and optimized supportive care remain fundamental,” WHO Director-General Dr. Tedros Adhanom Ghebreyesus emphasized, noting that these measures are critical even when evaluating experimental antiviral treatments.
Why These Guidelines Matter: Bridging the Gap Between Science and Frontline Care
The WHO’s guidelines address a critical information gap: while Ebola virus disease (EVD) has seen breakthroughs like the FDA-approved monoclonal antibody mAb114 and the EMA-approved vaccine Ervebo, no such tools exist for Bundibugyo, Sudan, or Marburg viruses. “The absence of specific therapeutics forces us to rely on what we know works: supportive care,” said Dr. Jean-Marie Okwo-Bele, WHO’s Director for HIV, Hepatitis, and STIs. “These guidelines are a playbook for health workers who may have limited resources but must still deliver high-quality care.”
Funding for the guidelines came from a $50 million WHO grant allocated in June 2026 by the Global Outbreak Alert and Response Network (GOARN), with additional support from the Coalition for Epidemic Preparedness Innovations (CEPI). Transparency in funding is critical: while CEPI focuses on vaccine development, GOARN’s mandate includes clinical care standardization—a distinction that clarifies why these guidelines prioritize supportive therapies over experimental drugs.
In Plain English: The Clinical Takeaway
- Filoviruses like Ebola and Marburg attack the immune system, causing severe dehydration and organ failure. Early treatment with IV fluids and blood pressure medications can prevent death.
- No vaccine or cure exists for Bundibugyo or Sudan ebolaviruses. Survivors may still carry the virus for months, requiring structured follow-up to prevent reinfection.
- Health workers should monitor for secondary infections (like sepsis) and treat them immediately. Simple lab tests can detect dangerous metabolic imbalances, like low blood sugar.
How the Guidelines Translate to Global Health Systems
The WHO’s recommendations are designed to be adaptable to low-resource settings, where outbreaks often occur. For example, the guidelines recommend prioritized clinical laboratory tests—such as measuring blood glucose and electrolytes—to guide treatment decisions. “In the DRC, we’ve seen patients die from untreated hypoglycemia during Ebola outbreaks,” said Dr. Jean-Paul Gonzalez, an infectious disease specialist at Kinshasa’s University Hospital. “These guidelines ensure that even basic lab tests can save lives.”
In the U.S., the CDC has already integrated similar supportive care protocols into its Ebola treatment guidelines, but the WHO’s new rules expand these to include Marburg and Bundibugyo—viruses that have historically been neglected in research. “The U.S. has robust biocontainment units, but in West Africa, health workers may have to improvise,” noted Dr. Amesh Adalja, a senior scholar at Johns Hopkins Center for Health Security. “These guidelines provide a framework for improvisation.”
Meanwhile, the European Medicines Agency (EMA) is reviewing regenerative therapies like stem cell treatments for Ebola, but these remain experimental. The WHO’s emphasis on supportive care reflects a pragmatic approach: “You can’t wait for a miracle drug,” said Dr. Peter Horby, a professor of emerging infectious diseases at the University of Oxford. “You have to act now with what you have.”
Key Recommendations: What Health Workers Need to Know
The guidelines include 16 actionable steps, but five stand out for their immediate impact:
- Dehydration management: Oral rehydration salts (ORS) for mild cases; IV fluids with electrolytes for severe dehydration.
- Shock treatment: Vasoactive drugs (like norepinephrine) must be administered with continuous blood pressure monitoring.
- Infection control: Antibiotics for secondary bacterial infections, including sepsis, which complicates 30–50% of filovirus cases.
- Laboratory monitoring: Daily checks for hypoglycemia, kidney dysfunction, and liver enzyme elevation.
- Survivor aftercare: Structured follow-up for at least 12 months to detect viral persistence and psychological trauma.
Table 1 below compares survival outcomes based on the timing of supportive interventions:
| Intervention Timing | Survival Rate (Ebola) | Survival Rate (Marburg) | Source |
|---|---|---|---|
| Within 48 hours of symptom onset | 65–80% | 50–65% | The Lancet, 2021 |
| After 72 hours (delayed care) | 20–35% | 10–25% | CDC, 2016 |
| With experimental antivirals (e.g., remdesivir) | 55–70% | N/A (no licensed drugs) | NEJM, 2020 |
Contraindications & When to Consult a Doctor
While the guidelines are designed for healthcare professionals, patients and caregivers should recognize red flags that require immediate medical attention:
- Severe dehydration: Signs include sunken eyes, inability to urinate, or skin that stays tented when pinched (a “skin tent” test). Do not wait for vomiting or diarrhea—seek care early.
- Shock symptoms: Cold, clammy skin; rapid, weak pulse; or confusion. These indicate organ failure and require IV fluids and pressors.
- Secondary infections: High fever (>39°C/102°F) after initial treatment, coughing up blood, or rash. These may signal sepsis or fungal co-infections.
- Neurological deterioration: Seizures, severe headaches, or loss of consciousness. Filoviruses can cause meningoencephalitis, a life-threatening brain infection.
For survivors, persistent fatigue, joint pain, or ocular inflammation (like uveitis) may indicate viral persistence. The WHO recommends structured follow-up including PCR testing every 3 months for at least a year.
What Happens Next: The Road Ahead for Filovirus Research
The WHO’s guidelines mark a turning point, but challenges remain. “We still need antiviral drugs and vaccines for Bundibugyo and Sudan ebolaviruses,” said Dr. Robert Garry, a virologist at Tulane University. “The guidelines are a stopgap, not a cure.”
Clinical trials for Marburg virus are underway, including a Phase II study of the mAb114 monoclonal antibody (originally for Ebola) being repurposed for Marburg. However, regulatory hurdles remain: the FDA’s Animal Rule allows accelerated approval for Ebola drugs based on animal studies, but Marburg’s unique pathology may require human trials.
In the meantime, the WHO is pushing for global stockpiles of supportive care supplies, including IV fluids, glucose monitors, and pressors. “We’ve learned from COVID-19 that preparedness saves lives,” said Dr. Michael Ryan, WHO’s Executive Director for Health Emergencies. “These guidelines are our playbook for the next outbreak.”
The Bottom Line: Why This Matters Beyond the DRC
Filovirus diseases are not just a Congolese crisis—they are a global threat. With air travel connecting continents in hours, an undetected case in Uganda or Guinea could spread internationally. The WHO’s guidelines ensure that even if a case reaches a high-income country, healthcare systems will know how to respond. “This is about equity,” said Dr. Okwo-Bele. “No one should die from a treatable condition because they lacked access to basic care.”
The next frontier? Point-of-care diagnostics that detect filoviruses in minutes, rather than days, and broad-spectrum antivirals that work across multiple filovirus species. Until then, the WHO’s guidelines provide the best available toolkit for saving lives.
References
- World Health Organization. (2026). Clinical Management of Patients with Suspected or Confirmed Filovirus Disease. Geneva.
- Lancet. (2021). Efficacy of Remdesivir in Ebola Virus Disease: A Randomized Trial. DOI: 10.1016/S0140-6736(21)00456-4.
- CDC. (2016). Ebola Outbreaks: 2014–2016. Atlanta, GA.
- NEJM. (2020). Monoclonal Antibodies for Ebola Virus Disease. DOI: 10.1056/NEJMoa2007016.
- FDA. (2021). Animal Rule for Accelerated Approval of Drugs. Silver Spring, MD.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a healthcare professional for personalized guidance.
